NQF announces support for 16 cancer quality measures

Luke Gale | | Health Exec | Economics

The National Quality Forum endorsed six new quality measures and reaffirmed its support for 10 existing quality measures related to the diagnosis and treatment of breast and colon cancers.

The new and existing measures, some of which have been endorsed for more than three years, were examined as part of a cancer endorsement maintenance project to ensure new and existing measures are harmonized, reflect current science and address gaps in existing measures, according to an Oct. 23 statement. The public is invited to request that NQF reconsider any of the 16 measures until Nov. 21.

Requests to reconsider measures can be made by submitting an appeal on the NQF measure database and the 16 recently endorsed measures are listed in a written statement from NQF.

Luke Gale

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.